Although these phenomena had not been seen in the included RCTs [7,10,11,16,17,18,41], the potential risk of potential enhancement of tumor growth by high-dose recombinant human erythropoietin still could not be excluded because the risk of potential enhancement of tumor growth need longer follow-up duration to approve its existence. This evidence concerns the gene EPO and neoplasm.